Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04916236 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers(SHERPA) | terminated | Phase 1 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03248479 | Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies | terminated | Phase 1 | 258 | Gilead SciencesINDUSTRY | 2 | Jan 17, 2025 |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 29 | Ichnos Sciences SAINDUSTRY | 3 | Jan 17, 2025 | clinicaltrials |
| NCT04171141 | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | terminated | Phase 1 | 79 | PfizerINDUSTRY | 3 | Jan 16, 2025 | clinicaltrials |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma | terminated | Phase 1 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 26 | CRISPR Therapeutics AGINDUSTRY | 4 | Jan 8, 2025 | clinicaltrials |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) | terminated | Phase 1 | 19 | CRISPR Therapeutics AGINDUSTRY | 4 | Jan 8, 2025 | clinicaltrials |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | terminated | Phase 1 | 49 | CRISPR Therapeutics AGINDUSTRY | 3 | Jan 8, 2025 | clinicaltrials |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer | terminated | Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05205161 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | terminated | Phase 1 | 7 | AstraZenecaINDUSTRY | 7 | Jan 7, 2025 | clinicaltrials |
| NCT03092635 | AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy | terminated | Phase 1 | 9 | Medical University of South CarolinaOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05100628 | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma | terminated | Phase 1 | 9 | Noxopharm LimitedINDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT04228042 | Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer | terminated | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03276676 | [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors | terminated | Phase 1 / Phase 2 | 10 | University of UtahOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03582033 | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | terminated | Phase 1 | 83 | Seagen Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)(KONQUER) | terminated | Phase 1 | 10 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05281276 | Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) | terminated | Phase 1 | 9 | Taipei Medical University Shuang Ho HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04214418 | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies(MEKiAUTO) | terminated | Phase 1 / Phase 2 | 27 | Columbia UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05176080 | Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05355753 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | terminated | Phase 1 | 49 | C4 Therapeutics, Inc.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 74 | Karyopharm Therapeutics IncINDUSTRY | 2 | Dec 16, 2024 | clinicaltrials |
| NCT04975256 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | terminated | Phase 1 | 7 | Mirati Therapeutics Inc.INDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors(CONTRAST) | terminated | Phase 1 / Phase 2 | 18 | BioInvent International ABINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 6 | ImmunityBio, Inc.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML(CYNK001AML01) | terminated | Phase 1 | 27 | Celularity IncorporatedINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05207722 | CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | terminated | Phase 1 / Phase 2 | 1 | Celularity IncorporatedINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | terminated | Phase 1 | 21 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation(Argonaut) | terminated | Phase 1 | 28 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 7 | Dec 12, 2024 | clinicaltrials |
| NCT03563157 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | terminated | Phase 1 / Phase 2 | 2 | ImmunityBio, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05917470 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | terminated | Phase 1 / Phase 2 | 21 | Oncternal Therapeutics, IncINDUSTRY | 2 | Dec 11, 2024 | clinicaltrials |
| NCT05350163 | T-cell Receptor α/β Depleted Donor Lymphocyte Infusion | terminated | Phase 1 | 11 | Guenther KoehneOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | terminated | Phase 1 | 52 | Taiho Oncology, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05999292 | Phase 1 Study of 68Ga-R8760 | terminated | Phase 1 | 11 | Radionetics OncologyINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04826198 | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months(REVOCAN) | terminated | Phase 1 / Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT05049863 | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) | terminated | Phase 1 | 17 | Washington University School of MedicineOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT02495233 | A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | terminated | Phase 1 / Phase 2 | 10 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04755244 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | terminated | Phase 1 | 14 | ALX Oncology Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)(PANAMA) | terminated | Phase 1 | 60 | Karyopharm Therapeutics IncINDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT02972034 | Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) | terminated | Phase 1 | 111 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT05824559 | ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer | terminated | Phase 1 | 23 | MEI Pharma, Inc.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03082300 | A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | terminated | Phase 1 | 3 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03166631 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | terminated | Phase 1 | 62 | Boehringer IngelheimINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03648372 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System | terminated | Phase 1 / Phase 2 | 109 | TakedaINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 24, 2025source: clinicaltrials